依达拉奉治疗急性脑梗死的临床观察及对IL-6和IL-13的影响

目的观察依达拉奉对急性脑梗死的临床疗效及其对血清白细胞介素6（IL-6）及白细胞介素13（IL-13）水平的影响。方法81例脑梗死患者，随机分为依达拉奉观察组（50例，依达拉奉＋常规治疗）与对照组（31例，常规治疗），检测治疗前和治疗后患者血清中IL-6和IL-13的变化，并观察其疗效。结果依达拉奉观察组临床疗效明显优于对照组，治疗后与对照组相比IL-6和IL-13水平下降较快（P〈0．01）。结论依达拉奉治疗急性脑梗死有效，而且安全。

The effective clinical study of Edaravone on treatment of cerebral infarction and the changes of IL-6 and IL-13 in serum

Objective To detect their expressions of IL-6 and IL-13, and the relationship with Edaravone in cerebral infarction,and investigate their clinical significance. Methods 81 cases with cerebral infarction were divided into two groups. The observation group（50 cases）was treated by routine and Edaravone treatment. The control group（31 cases）was treated by routine treatment. The expressions of IL-6 and IL-13 were detected in pre-treatment and post-treatment of Edaravone. We observed their efficacy of Edaravone. Results The expressions of IL-6 and IL-13 were obviously significant in pre-treatment and post-treatment by Edaravone. But the decrease of IL-6 and IL-13 were higher in the observation group than in the control group. The total effeetive rate was obviously higher in the observation group than in the control group. Conclusion The Edaravone can inhibit the expressions of IL-6 and IL-13, and protect the cerebral cells in cerebral infarction.